Levothyroxine formulations
    2.
    发明授权
    Levothyroxine formulations 有权
    左甲状腺素制剂

    公开(公告)号:US09006289B2

    公开(公告)日:2015-04-14

    申请号:US13597884

    申请日:2012-08-29

    摘要: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 1 to 5 milligrams mannitol. The composition may include from 100 to 200 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 40:1. The composition may include about 500 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 10:1.

    摘要翻译: 左甲状腺素组合物包括左甲状腺素钠和甘露糖醇。 组合物是固体。 该组合物可以包含100至500微克左旋甲状腺素钠和1至5毫克甘露醇。 组合物可以包含100至200微克左甲状腺素钠,组合物中甘露醇与左甲状腺素钠的质量比可以至多为40:1。 组合物可以包含约500微克左甲状腺素钠,组合物中甘露醇与左甲状腺素钠的质量比可以至多为10:1。

    Levothyroxine Formulations
    3.
    发明申请
    Levothyroxine Formulations 有权
    左甲状腺素制剂

    公开(公告)号:US20130053445A1

    公开(公告)日:2013-02-28

    申请号:US13597884

    申请日:2012-08-29

    IPC分类号: A61K31/198

    摘要: A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 1 to 5 milligrams mannitol. The composition may include from 100 to 200 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 40:1. The composition may include about 500 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 10:1.

    摘要翻译: 左甲状腺素组合物包括左甲状腺素钠和甘露糖醇。 组合物是固体。 该组合物可以包含100至500微克左旋甲状腺素钠和1至5毫克甘露醇。 组合物可以包含100至200微克左甲状腺素钠,组合物中甘露糖醇与左甲状腺素钠的质量比可以至多为40:1。 组合物可以包含约500微克左甲状腺素钠,组合物中甘露醇与左甲状腺素钠的质量比可以至多为10:1。

    Bortezomib Formulations
    4.
    发明申请
    Bortezomib Formulations 有权
    硼替佐米配方

    公开(公告)号:US20120083457A1

    公开(公告)日:2012-04-05

    申请号:US13252421

    申请日:2011-10-04

    IPC分类号: A61K38/05

    摘要: A bortezomib composition includes bortezomib and boric acid in a mass ratio of boric acid to bortezomib is from 1:1 to 10:1. The composition is a solid, and may be prepared by forming a liquid mixture including a solvent, bortezomib and boric acid, and lyophilizing the liquid mixture.

    摘要翻译: 硼替佐米组合物包括硼替佐米和硼酸,硼酸与硼替佐米的质量比为1:1至10:1。 该组合物是固体,并且可以通过形成包含溶剂,硼替佐米和硼酸的液体混合物并且将液体混合物冻干来制备。